Quality by Design for Generic Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Quality by Design for Generic Drugs
The authors relay the outcome of a two-day workshop that brought together regulators and generic-drug industry representatives.


Pharmaceutical Technology
Volume 33, Issue 10, pp. 122-127

References

1. ICH, ICH Q8(R1) Pharmaceutical Development/Annex (Geneva, November 2008).

2. L. X. Yu. "Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control," Pharm. Res. 25 (4), 781–791 (2008).

3. R. Lionberger et al., "Quality by Design: Concepts for ANDAs," The AAPS Journal. 10 (2), 268–276 (2008).

4. L. S. Lee, A. Raw, and L. X. Yu, "Dissolution Testing," in Biopharmaceutics Applications in Drug Development, R. Krishna and Lawrence X. Yu, Eds. (Springer, New York, NY, 2008), pp. 47–74.

5. ICH, ICH Q9 Quality Risk Management (Geneva, November 2005).

6. ICH Quality Implementation Working Group, Q8, Q9, and Q10 Questions and Answers, http://www.ich.org/LOB/media/MEDIA5290.pdf, accessed Aug. 26, 2009.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here